| Name | FPL 62064 |
| Description | FPL 62064 is a potent dual inhibitor of 5-lipoxygenase (5-LOX) and COX (IC50 of 3.5 μM and 3.1 μM for RBL-1 cytosolic 5-lipoxygenase and prostaglandin synthetase, respectively). |
| Animal Research | Animal Model:Female LACA mice (20-30 g) injected with immune complex. Dosage:5 mg/kg, 10 mg/kg, 20 mg/kg. Administration:Intraperitoneal injection. |
| In vivo | FPL 62064 inhibited UV irradiation-induced erythema and PGE2 formation in the guinea pig and also oedema formation and eicosanoid production in the mouse ear produced by arachidonic acid. Co-injected with arachidonic acid in rabbit skin, FPL 62064 inhibited oedema and eicosanoid formation. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 250 mg/mL (942.29 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (18.85 mM), Sonication is recommended.
|
| Keywords | synthetase | Prostaglandin | LOX | Lipoxygenase | Inhibitor | inhibit | FPL-62064 | FPL62064 | FPL 62064 | Cyclooxygenase | COX-2 | COX | anti-inflammatory | 5-LOX | 5-lipoxygenase |
| Inhibitors Related | Naproxen sodium | Acetaminophen | Phenidone | 4-Aminosalicylic acid | Gallic Acid Monohydrate | Diclofenac Potassium | Paradol | Trometamol | 5-Methylfurfural | Phenylbutazone | Revaprazan hydrochloride | Magnesium sulfate |
| Related Compound Libraries | Ferroptosis Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Neuronal Signaling Compound Library | ReFRAME Related Library | Inhibitor Library | NO PAINS Compound Library | Lipid Metabolism Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Cosmetic Ingredient Compound Library | Bioactive Compounds Library Max |